MindWalk Holdings Files Q3 2026 MD&A and Interim Financials

MindWalk Holdings ( (HYFT) ) has issued an update.

MindWalk Holdings Corp. has filed a Form 6-K for March 2026, furnishing its management’s discussion and analysis and condensed interim consolidated financial statements for the three- and nine-month periods ended January 31, 2026 and 2025. The filing, approved by the board on March 11, 2026 and signed by CEO Jennifer Bath on March 12, 2026, also includes CEO and CFO certifications under Canadian regulations, reinforcing the company’s ongoing disclosure and compliance obligations to investors in Canada and the United States.

The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

Spark’s Take on HYFT Stock

According to Spark, TipRanks’ AI Analyst, HYFT is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improved gross margin, and a stronger cash position, but valuation remains constrained by negative earnings.

To see Spark’s full report on HYFT stock, click here.

More about MindWalk Holdings

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company operating at the intersection of artificial intelligence, deep biological data and advanced laboratory research. Listed on the Nasdaq Capital Market under the ticker HYFT, it runs an integrated in silico and wet-lab discovery platform that has supported the clinical advancement of more than 15 molecules for clients and partners.

Average Trading Volume: 551,535

Technical Sentiment Signal: Sell

Current Market Cap: $59.76M

See more insights into HYFT stock on TipRanks’ Stock Analysis page.